Novel treatments and guideline updates are frequent occurrences in many common blood malignancies in the United States. Review the latest breakthroughs involving treatment guidelines, real-world toxicities, prognostic indicators, and outcomes research in chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML).
In recent months, newly available literature and breaking discoveries have changed our understanding of treatment options, prognostic indicators, and value in various types of sarcoma. Review the latest research breakthroughs involving sarcoma targeted therapies, surgical options, disease burden, and aftercare strategies.
Within the past 3 months, there have been multiple updates to guidelines for a variety of cancers and diseases released. The treatment landscape has been evolving in malignancies such as cervical, vulvar, gastric, lung, skin, and multiple myeloma, as well as diabetes. The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have updated a few of their guidelines to reflect these changes.
B-cell malignancies are among the most deadly and difficult-to-treat blood disorders. Our understanding of treatment options, prognostic indicators, and value in B-cell malignancies is constantly evolving. Within the past 6 months, there have been numerous breakthroughs in B-cell malignancy therapies, biomarkers, prognoses, and mutational understandings. Review the late breakthroughs in this field since the early summer.